| Cat. No. : |
BMP6-68H |
| Description : |
Bone Morphogenetic Protein 6 (BMP-6), also known as Vgr-1, is one of at least 15 structurally and functionally related BMPs which are members of the transforming growth factor β (TGF-β) superfamily. Human BMP-6 is synthesized as a 513 amino acid (aa) precursor protein that is cleaved at the dibasic cleavage site (RxxR) to release the 18 kDa C-terminal mature protein. Biologically active BMP -6 consists of a disulfide-linked homodimer of the mature proteins. Mature human BMP-6 shares 96% and 98% aa sequence identity with mouse and rat BMP-6, respectively. Cellular responses to BMP-6 are mediated by hetero-oligomeric complexes of type I (Activin RIA/ALK -2 and BMPR-IA/ALK-3) and type II (Activin RIIA and BMPR-II) serine/threonine kinase receptors. Glycosylation of BMP-6 is required for its interaction with Activin RIA. BMP6 induces the expression of Noggin and is subsequently antagonized by Noggin. BMP-6 induces a wide range of cellular responses. It promotes osteoblast differentiation from mesenchymal stem cells, chondrocyte maturation (9), Ang II-induced aldosterone production in the adrenal cortex, hormone production and responsiveness in ovarian granulosa cells, iNOS and TNF-α production in macrophages, the cell death of B cells, and neurite outgrowth. BMP-6 expression is induced in astrocytes surrounding sites of brain injury where it functions as a neuroprotectant. BMP-6 is up-regulated during prostate cancer progression and promotes tumor cell metastasis to bone. Through interactions with the BMP coreceptor RGM-C/Hemojuvelin, BMP-6 plays an important role in iron homeostasis by promoting Hepcidin expression and preventing serum iron overload. |
| Source : |
Mammalian cells |
| Sequence : |
Gln382-His513 |
| SDS-PAGE : |
18 kDa, reducing conditions |
| Activity : |
Measured by its ability to induce alkaline phosphatase production by ATDC5 mouse chondrogenic cells. The ED50 for this effect is typically 0.02-0.15 μg/mL. |
| Endotoxin Level : |
<1.0 EU per 1 μg of the protein by the LAL method. |
| Purity : |
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain. |
| Formulation : |
Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with BSA as a carrier protein. See Certificate of Analysis for details. |
| Reconstitution : |
Reconstitute at 100 μg/mL in sterile 4 mMHCl containing at least 0.1% human or bovine serum albumin. |
| Shipping : |
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability &Storage : |
Use a manual defrost freezer and avoid repeated freeze/thaw cycles. 12 months from date of receipt, 20 to 70°C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, 20 to 70 °C under sterile conditions after reconstitution. |
